Literature DB >> 11832722

The BTA stat test is nonspecific for hematuria: an experimental hematuria model.

Omer Oge1, Didem Kozaci, Hakan Gemalmaz.   

Abstract

PURPOSE: An experimental hematuria model was designed to determine whether the bladder tumor antigen (BTA) stat test (Bion Diagnostics, Redmond, Washington) is influenced by microscopic or macroscopic hematuria.
MATERIALS AND METHODS: A total of 25 healthy subjects provided urine and blood samples for the study. All subjects had a negative BTA stat test initially. Normal urine was mixed with autologous blood to cause hematuria of 3 degrees of severity. The test was performed in each sample after the creation of hematuria.
RESULTS: BTA stat assay specificity in the presence of microscopic and gross hematuria was 80% and 24%, respectively. Results varied depending on the severity of hematuria, that is 20% for microscopic and 76% for gross hematuria.
CONCLUSIONS: The results of the BTA stat test in the presence of microscopic hematuria must be interpreted in regard to the degree of hematuria. The test is not reliable in urine samples with gross hematuria due to a high false-positive rate.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11832722     DOI: 10.1016/s0022-5347(05)65290-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

1.  No influence of smoking status on the performance of urine markers for the detection of bladder cancer.

Authors:  Susanne Deininger; J Hennenlotter; S Rausch; K Docktor; E Neumann; I A da Costa; J Bedke; A Stenzl; T Todenhöfer
Journal:  J Cancer Res Clin Oncol       Date:  2018-04-19       Impact factor: 4.553

2.  Urine cytology and adjunct markers for detection and surveillance of bladder cancer.

Authors:  Peggy S Sullivan; Jessica B Chan; Mary R Levin; Jianyu Rao
Journal:  Am J Transl Res       Date:  2010-07-25       Impact factor: 4.060

3.  Urinary BTA: indicator of bladder cancer or of hematuria.

Authors:  Makito Miyake; Steve Goodison; Wasia Rizwani; Shanti Ross; H Bart Grossman; Charles J Rosser
Journal:  World J Urol       Date:  2012-08-30       Impact factor: 4.226

4.  [Role of immunocytology in the evaluation of patients with painless gross hematuria].

Authors:  B J Schmitz-Dräger; L-A Tirsar; C Schmitz-Dräger; J Dörsam; T Ebert; E Bismarck
Journal:  Urologe A       Date:  2010-06       Impact factor: 0.639

5.  Critical evaluation of urinary markers for bladder cancer detection and monitoring.

Authors:  Shahrokh F Shariat; Jose A Karam; Yair Lotan; Pierre I Karakiewizc
Journal:  Rev Urol       Date:  2008

6.  Immunocytology in the assessment of patients with asymptomatic hematuria.

Authors:  B J Schmitz-Dräger; L-A Tirsar; C Schmitz-Dräger; J Dörsam; Z Mellan; E Bismarck; T Ebert
Journal:  World J Urol       Date:  2007-12-12       Impact factor: 4.226

7.  [Urine marker systems for diagnosis of urothelial cancer].

Authors:  S Tritschler; F Strittmatter; A Karl; C Stief
Journal:  Urologe A       Date:  2013-07       Impact factor: 0.639

8.  IL-8 as a urinary biomarker for the detection of bladder cancer.

Authors:  Virginia Urquidi; Myron Chang; Yunfeng Dai; Jeongsoon Kim; Edward D Wolfson; Steve Goodison; Charles J Rosser
Journal:  BMC Urol       Date:  2012-05-04       Impact factor: 2.264

9.  Influencing factors on the NMP-22 urine assay: an experimental model.

Authors:  Makito Miyake; Steve Goodison; Evan Gomes Giacoia; Wasia Rizwani; Shanti Ross; Charles J Rosser
Journal:  BMC Urol       Date:  2012-08-28       Impact factor: 2.264

Review 10.  Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests.

Authors:  Steve Goodison; Charles J Rosser; Virginia Urquidi
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.